N L Zaharan1, D Williams, K Bennett. 1. Department of Pharmacology, Faculty of Medicine, University Malaya, Lembah Pantai, 50603, Kuala Lumpur, Malaysia, nurlisazaharan@um.edu.my.
Abstract
BACKGROUND: Over the last decade there have been significant changes in the prescribing of antidiabetic therapies. It is of interest to know about these trends and variations in the Irish population so that future prescribing patterns can be estimated. AIMS: To examine the trends in prescribed antidiabetic treatments, including variations across age, gender, socioeconomic status and regions in the Irish population over the last 10 years. METHODS: The Irish national pharmacy claims database was used to identify patients ≥ 16 years dispensed antidiabetic agents (oral or insulin) from January 2003 to December 2012 through the two main community drug schemes for diabetes. The rate of prescribing per 1,000 population was calculated. Logistic regression was used to examine variations in prescribing in patients with diabetes. RESULTS: There was a significant increase in the prescribing of fast and long-acting insulin analogues with a rapid decline in the prescribing of human insulin (p < 0.0001). Increased prescribing of metformin, incretin modulators and fixed oral combination agents was observed (p < 0.0001). Females and older aged patients were more likely to be prescribed human insulin than other insulins. Metformin was less likely while sulphonylureas were more likely to be prescribed in older than younger aged patients. Socioeconomic differences were observed in increased prescribing of the newer and more expensive antidiabetic agents in the non-means tested scheme. Regional variations were observed in the prescribing of both insulin and oral antidiabetic agents. CONCLUSION: There has been an increase over time in the prescribing of both insulin and oral antidiabetic agents in the Irish population with increasing uptake of newer antidiabetic agents. This has implications for projecting future uptake and expenditure of these agents given the rising level of diabetes in the population.
BACKGROUND: Over the last decade there have been significant changes in the prescribing of antidiabetic therapies. It is of interest to know about these trends and variations in the Irish population so that future prescribing patterns can be estimated. AIMS: To examine the trends in prescribed antidiabetic treatments, including variations across age, gender, socioeconomic status and regions in the Irish population over the last 10 years. METHODS: The Irish national pharmacy claims database was used to identify patients ≥ 16 years dispensed antidiabetic agents (oral or insulin) from January 2003 to December 2012 through the two main community drug schemes for diabetes. The rate of prescribing per 1,000 population was calculated. Logistic regression was used to examine variations in prescribing in patients with diabetes. RESULTS: There was a significant increase in the prescribing of fast and long-acting insulin analogues with a rapid decline in the prescribing of humaninsulin (p < 0.0001). Increased prescribing of metformin, incretin modulators and fixed oral combination agents was observed (p < 0.0001). Females and older aged patients were more likely to be prescribed humaninsulin than other insulins. Metformin was less likely while sulphonylureas were more likely to be prescribed in older than younger aged patients. Socioeconomic differences were observed in increased prescribing of the newer and more expensive antidiabetic agents in the non-means tested scheme. Regional variations were observed in the prescribing of both insulin and oral antidiabetic agents. CONCLUSION: There has been an increase over time in the prescribing of both insulin and oral antidiabetic agents in the Irish population with increasing uptake of newer antidiabetic agents. This has implications for projecting future uptake and expenditure of these agents given the rising level of diabetes in the population.
Authors: A Siebenhofer; J Plank; A Berghold; K Jeitler; K Horvath; M Narath; R Gfrerer; T R Pieber Journal: Cochrane Database Syst Rev Date: 2006-04-19
Authors: A Melander; P Folino-Gallo; T Walley; U Schwabe; P-H Groop; T Klaukka; A Vallano; J-R Laporte; M R Gallego; M Schiappa; M Røder; J P Kampmann; A de Swaef; M Aberg; N-O Månsson; U Lindblad Journal: Diabetologia Date: 2006-07-25 Impact factor: 10.122
Authors: Kristian B Filion; Lawrence Joseph; Jean-François Boivin; Samy Suissa; James M Brophy Journal: Pharmacoepidemiol Drug Saf Date: 2009-10 Impact factor: 2.890
Authors: Ronan T Grimes; Kathleen Bennett; Lesley Tilson; Cara Usher; Susan M Smith; Martin C Henman Journal: Br J Clin Pharmacol Date: 2015-06 Impact factor: 4.335
Authors: J Moon; S S Kumar; G G Graham; M T Baysari; K M Williams; W Chen; A Viardot; J R Greenfield; R O Day Journal: Eur J Clin Pharmacol Date: 2016-08-27 Impact factor: 2.953
Authors: Andrzej Śliwczyński; Melania Brzozowska; Andrzej Jacyna; Petre Iltchev; Tymoteusz Iwańczuk; Waldemar Wierzba; Michał Marczak; Katarzyna Orlewska; Piotr Szymański; Ewa Orlewska Journal: PLoS One Date: 2017-06-05 Impact factor: 3.240
Authors: Kristin K Clemens; Salimah Shariff; Kuan Liu; Irene Hramiak; Jeffrey L Mahon; Eric McArthur; Amit X Garg Journal: PLoS One Date: 2015-09-03 Impact factor: 3.240
Authors: Jared M Campbell; Matthew D Stephenson; Barbora de Courten; Ian Chapman; Susan M Bellman; Edoardo Aromataris Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472